Omega Therapeutics (OMGA)
(Delayed Data from NSDQ)
$1.32 USD
+0.06 (4.76%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $1.32 0.00 (0.00%) 6:46 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OMGA 1.32 +0.06(4.76%)
Will OMGA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for OMGA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OMGA
Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates
Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?
OMGA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates
Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?
Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for OMGA
Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry
Omega Pacific Issues Common Shares for Three Additional Claims in the Golden Horseshoe Area in British Columbia
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
Omega Therapeutics announces publication of preclinical data of OTX-2002
Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research